Decitabine, Venetoclax, and Olutasidenib for IDH1-Mutated Blood Cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial combines three drugs—decitabine, venetoclax, and a targeted therapy (olutasidenib)—to treat acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has come back or is not responding to treatment. It may also be an option for people newly diagnosed with AML who cannot receive intense chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have an IDH1 mutation in your cancer cells.
- You have AML that has returned or is not responding, or high-risk MDS.
- If newly diagnosed with AML, you must be 75 or older, or 18-74 with a health condition that makes intensive chemo unsafe.
- You are over 18 years old.
- Your kidney and liver function tests must be within certain limits (some flexibility depending on your situation).
- You must not be pregnant or nursing, and must agree to use effective birth control if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of olutasidenib, venetoclax, and azacitidine for people with newly diagnosed acute myeloid leukemia (AML) that has an IDH1 mutation. It is for patients who are healthy enough for intensive chemotherapy. The goal is to see if this drug combination works better than standard treatment.
This trial tests an oral drug called olutasidenib in people with certain low-risk blood cancers or a pre-cancer condition. It may help by targeting a specific genetic change (IDH1 mutation) found in your blood cells.
This trial tests a combination of olutasidenib with other targeted drugs for people with certain blood cancers that have returned or not responded to treatment. It focuses on patients who have both an IDH1 mutation and a second activating mutation in specific signaling genes.
This trial tests the drug olutasidenib for people with a specific type of acute myeloid leukemia (AML) that has come back or not responded to treatment. It is for patients who have already received the drug venetoclax and have an IDH1 mutation in their leukemia cells.
This trial tests a targeted drug, olutasidenib, for people with AML or MDS whose cancer cells have an IDH1-R132 mutation. Depending on your specific diagnosis, you may receive olutasidenib alone or combined with other medicines.
This trial tests whether adding the targeted therapy olutasidenib to the chemotherapy drug azacitidine can help people with a certain type of AML (one with an IDH1 mutation) who have already had some treatment but still have the disease. The goal is to see if this combination can lead to a longer remission.
Hear when a new Mutant IDH1 Inhibitor Olutasidenib trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.